RA Capital Management 13F holdings, Q4 2009
Holdings as of December 31, 2009 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 14 US equity positions worth $75.1m in its Q4 2009 13F filing. The largest position was BSTC at 32.9% of the reported book, followed by OSI PHARMACEUTICALS INC and PHARMASSET INC. Against the Q2 2009 filing, it opened 9 new positions, added to 2 and reduced 3 among the top 14 holdings.
What did RA Capital Management own in Q4 2009? Top 14 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2009 |
|---|---|---|---|---|---|---|---|
| 1 | BSTC BIOSPECIFICS TECHNOLOGIES CO | 32.9% | $24.7m | 841,603 | – | new | |
| 2 | OSI PHARMACEUTICALS INC | 11.0% | $8.2m | 264,886 | 657% | added | |
| 3 | PHARMASSET INC | 9.7% | $7.2m | 350,260 | -45% | reduced | |
| 4 | AMAG AMAG PHARMACEUTICALS INC | 9.2% | $6.9m | 180,978 | 202% | added | |
| 5 | DENDREON CORP | 8.5% | $6.4m | 242,294 | -40% | reduced | |
| 6 | ADR NEW | 7.2% | $5.4m | 3,800,000 | – | new | |
| 7 | GILD GILEAD SCIENCES INC | Healthcare | 6.7% | $5.0m | 116,400 | -68% | reduced |
| 8 | MAP PHARMACEUTICALS INC | 6.7% | $5.0m | 524,982 | – | new | |
| 9 | COLUMBIA LABS INC | 3.9% | $3.0m | 2,732,300 | – | new | |
| 10 | IDENIX PHARMACEUTICALS INC | 2.9% | $2.2m | 1,017,187 | – | new | |
| 11 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 0.6% | $474.0k | 174,425 | – | new |
| 12 | TELIK INC | 0.5% | $372.0k | 474,113 | – | new | |
| 13 | CHINA BIOLOGIC PRODS INC | 0.2% | $139.0k | 11,500 | – | new | |
| 14 | LIGAND PHARMACEUTICALS INC | 0.0% | $29.0k | 13,200 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.